Literature DB >> 31851535

CXCR2 Signaling and Remyelination in Preclinical Models of Demyelination.

Dominic D Skinner1, Thomas E Lane1.   

Abstract

The chemokine receptor CXCR2 is a receptor for CXC chemokines, including CXCL1 and CXCL2. CXCR2 is expressed by resident cells of the central nervous system, including neurons, microglia, oligodendrocyte progenitor cells (OPCs), and oligodendrocytes. CXCR2 signaling is important in regulating OPC biology with regard to positional migration and myelination during development. More recently, studies have argued that CXCR2 is involved in controlling events related to remyelination after experimentally induced demyelination. This review examines the concept that targeting CXCR2 may offer a novel therapeutic target for promoting remyelination.

Entities:  

Keywords:  chemokine receptors; demyelination; oligodendrocyte; remyelination

Mesh:

Substances:

Year:  2019        PMID: 31851535      PMCID: PMC6978782          DOI: 10.1089/dna.2019.5182

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  48 in total

1.  Expression of chemokine receptors by subsets of neurons in the central nervous system.

Authors:  R Horuk; A W Martin; Z Wang; L Schweitzer; A Gerassimides; H Guo; Z Lu; J Hesselgesser; H D Perez; J Kim; J Parker; T J Hadley; S C Peiper
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

2.  Theiler's virus induces the MIP-2 chemokine (CXCL2) in astrocytes from genetically susceptible but not from resistant mouse strains.

Authors:  Nazario Rubio; Francisco Sanz-Rodriguez; Howard L Lipton
Journal:  Cell Immunol       Date:  2006-05-08       Impact factor: 4.868

3.  Role for CXCR2 and CXCL1 on glia in multiple sclerosis.

Authors:  Kakuri M Omari; Gareth John; Richard Lango; Cedric S Raine
Journal:  Glia       Date:  2006-01-01       Impact factor: 7.452

Review 4.  Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.

Authors:  L Steinman
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

5.  CXC chemokine receptors expression during chronic relapsing experimental autoimmune encephalomyelitis.

Authors:  A R Glabinski; S O'Bryant; K Selmaj; R M Ransohoff
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 6.  Regulation of oligodendrocyte differentiation: Insights and approaches for the management of neurodegenerative disease.

Authors:  Abdullah Mohammad Tauheed; Joseph Olusegun Ayo; Mohammed Umaru Kawu
Journal:  Pathophysiology       Date:  2016-05-31

7.  GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions.

Authors:  R Filipovic; I Jakovcevski; N Zecevic
Journal:  Dev Neurosci       Date:  2003 Mar-Aug       Impact factor: 2.984

8.  Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in promoting axon myelination.

Authors:  Hawra Karim; Sung Hoon Kim; Andrew S Lapato; Norio Yasui; John A Katzenellenbogen; Seema K Tiwari-Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

9.  Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis.

Authors:  Hawra Karim; Sung Hoon Kim; Kelli Lauderdale; Andrew S Lapato; Kelley Atkinson; Norio Yasui; Hana Yamate-Morgan; Maria Sekyi; John A Katzenellenbogen; Seema K Tiwari-Woodruff
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

10.  The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease.

Authors:  Thaddeus Carlson; Mark Kroenke; Praveen Rao; Thomas E Lane; Benjamin Segal
Journal:  J Exp Med       Date:  2008-03-17       Impact factor: 14.307

View more
  1 in total

Review 1.  25-Hydroxycholesterol as a Signaling Molecule of the Nervous System.

Authors:  Ulia G Odnoshivkina; Eva A Kuznetsova; Alexey M Petrov
Journal:  Biochemistry (Mosc)       Date:  2022-06       Impact factor: 2.824

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.